Nasdaq Leads Rebound, Biotech Sees Breakouts, and Telehealth Scores Weight-Loss Win

Markets swung early but finished the day with strong momentum as several major developments drove investor attention. Biotech stocks led the charge after multiple drug trials delivered promising results, sending several names sharply higher.

In healthcare, a telehealth platform made a major move by securing access to the world’s most in-demand weight-loss medications, instantly boosting its credibility. Meanwhile, one small-cap stock stunned the market with a triple-digit surge, highlighting just how quickly momentum can build when investors pile into the right story.

Want an edge before the opening bell? 9fin tracks credit signals across 4,000+ companies in real-time—covenant breaches, refinancing struggles, credit events that move stock prices.

Credit markets signal trouble (or opportunity) before it hits equities.

Get alerts institutional traders use.

Try 9fin Free

Job reports and oil surges hit indexes early in the day but turned around following Trump’s announcement that the war with Iran could end sooner than we think. The Nasdaq saw the biggest boon, jumping back almost one and a half percent.

Agilent Technologies (NYSE: A) just agreed to acquire Biocare Medical for $950 million in cash.

Biocare makes tissue diagnostic products used to identify cancer and infectious diseases in pathology labs.

The deal adds over 300 antibodies, staining machines, and specialized tools that help pathologists read tissue slides and make diagnoses.

Agilent already operates in this space. This acquisition makes it significantly stronger.

Pathology Is Where Treatment Decisions Begin

Before any cancer patient receives treatment, a pathologist examines tissue samples to determine the type of cancer.

The tools used in that process, the antibodies, the staining systems, and the software directly shape the diagnosis. Agilent is deepening its investment in that critical first step.

You rarely hear about this part of healthcare because it happens behind the scenes. But every treatment plan starts with the work these machines and products make possible.

Revenue Impact Starts Immediately

Agilent expects the acquisition to boost both revenue growth and profitability within the first year.

That speed matters because it signals strong product overlap and an existing customer base that Agilent can sell into right away.

You see a company that did not buy potential.

It bought a business already generating revenue in a category where demand for better diagnostic tools only grows as cancer detection becomes more precise.

Duke Energy (NYSE: DUK) just raised $1 billion through a new bond offering.

The money primarily goes toward paying down existing debt that comes due next year, with the rest available for general business needs.

Duke recently raised its five-year spending plan to $103 billion, the largest capital commitment of any regulated utility in the country.

The Spending Demands Constant Fuel

Building new power generation, expanding transmission lines, adding battery storage, and modernizing aging infrastructure across multiple states requires a constant flow of capital.

Duke cannot fund a $103 billion plan solely from electricity bills.

You think about what it takes to rebuild the grid while simultaneously keeping the lights on for millions of customers, and the financial scale starts to make sense.

Every billion raised is another piece of that puzzle falling into place.

The Bigger Picture

Duke is not raising money because it is struggling. It is raising money because the opportunity ahead is enormous, and the grid cannot wait.

Every new bond offering funds the infrastructure that keeps the company at the center of America's energy transition.

You connect the $1 billion raise to the $103 billion plan, and the strategy is clear.

Duke is spending aggressively now to own the grid that powers the next generation of American energy demand.

I predicted the 1987 crash six weeks early. I called the fall of the Berlin Wall. I pinpointed the exact bottom in 2009.

Now I'm staking my reputation on March 26, 2026 - the day I believe Elon will announce the SpaceX IPO.

Bloomberg is calling it "the biggest listing of ALL TIME."

A $1.5 TRILLION valuation... the "wealth-building" moment of the decade.

Today, I'll show you how to get in before the big announcement.

Click Here to See How to Secure Your "SpaceX Access Code"

Hims & Hers Health (NYSE: HIMS) just secured a deal to sell Wegovy and Ozempic directly through its platform.

These are the two most in-demand weight loss and diabetes drugs in the world, both made by Novo Nordisk.

Just weeks ago, Novo was suing Hims over a cheap copycat version of its obesity pill. Now the two companies are partners.

That is one of the fastest pivots from courtroom to handshake the healthcare industry has seen in years.

Credibility Just Jumped Overnight

Selling compounded knockoffs positioned Hims as a discount alternative. Selling the real Wegovy and Ozempic at Novo's self-pay prices repositions the entire brand.

Hims goes from scrappy telehealth disruptor to legitimate channel for the biggest pharmaceutical products in the market.

If your view of Hims has been shaped by cheap alternatives and legal controversy, this deal completely rewrites the narrative.

The Tradeoff Is Real

Branded drugs bring higher revenue but lower margins than the compounded versions Hims was selling before.

The company trades some profitability per prescription for legitimacy, volume, and a partnership that no competitor in telehealth currently has.

You can debate whether the margin tradeoff makes sense long-term.

But having Wegovy and Ozempic on your platform is the kind of credibility that money alone cannot buy, and Hims just got it for free by ending a fight it was probably going to lose anyway.

👉 Click here to get our closing report to your cell for free!

Garden Stage Limited [GSIW] $33.21 (+248.11%)

Garden Stage saw a big jump in share price after a recent reverse split caught investor attention.

Xenon Pharmaceuticals [XENE] $62.76 (+49.64%)

Xenon Pharmaceuticals hit a big win in its epilepsy drug’s Phase III study results.

Dianthus Therapeutics Inc [DNTH] $79.23 (+21.52%)

Dianthus Therapeutics stock rallied after its rare-disease study saw positive impact.

Olema Therapeutics [OLMA] $16.00 (-25.75%)

Olema Therapeutics lost ground after news broke that Roche’s phase 3 breast cancer study showed middling results.

Brand Engagement Network [BNAI] $41.95 (-25.45%)

Bçnd Engagement Network dropped after receiving a scathing review from Jim Cramer during his lightning round.

Evolution Metals & Technologies [EMAT] $8.17 (-16.29%)

Evolution Metals and Technologies dealt with the ups and downs of post-SPAC volatility, ending the day at a low point.

Big Oil may be facing its biggest challenge yet.

A breakthrough tied to an MIT-trained scientist could unlock a fuel source that’s virtually unlimited.

According to the U.S. Department of Energy, it could last billions of years.

Once operational, the fuel itself costs nothing.

That’s why this story matters now.

Get the full details here.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.